Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK

H. M. Earl; L. Hiller; J. Dunn; I. Macpherson; D. Rea; L. Hughes-Davies; K. McAdam; P. Hall; J. Mansi; D. Wheatley; J. E. Abraham; C. Caldas; S. Gasson; E. O'Riordan; M. Wilcox; D. Miles; D. A. Cameron; A. Wardley

doi:10.1016/j.clon.2020.07.006

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK

H. M. Earl^*
, L. Hiller
, J. Dunn
, I. Macpherson
, D. Rea
, L. Hughes-Davies
, K. McAdam
, P. Hall
, J. Mansi
, D. Wheatley
, J. E. Abraham
, C. Caldas
, S. Gasson
, E. O'Riordan
, M. Wilcox
, D. Miles
, D. A. Cameron
, A. Wardley

^*Corresponding author for this work

Research output: Contribution to journal › Editorial

2 Scopus citations

Original language	English
Pages (from-to)	15-19
Number of pages	5
Journal	Clinical Oncology
Volume	33
Issue number	1
DOIs	https://doi.org/10.1016/j.clon.2020.07.006
State	Published - Jan 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.clon.2020.07.006

Cite this

Earl, H. M., Hiller, L., Dunn, J., Macpherson, I., Rea, D., Hughes-Davies, L., McAdam, K., Hall, P., Mansi, J., Wheatley, D., Abraham, J. E., Caldas, C., Gasson, S., O'Riordan, E., Wilcox, M., Miles, D., Cameron, D. A., & Wardley, A. (2021). Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK. Clinical Oncology, 33(1), 15-19. https://doi.org/10.1016/j.clon.2020.07.006

@article{63bb58e5239541d685ab49e37d5ff7c2,

title = "Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK",

author = "Earl, \{H. M.\} and L. Hiller and J. Dunn and I. Macpherson and D. Rea and L. Hughes-Davies and K. McAdam and P. Hall and J. Mansi and D. Wheatley and Abraham, \{J. E.\} and C. Caldas and S. Gasson and E. O'Riordan and M. Wilcox and D. Miles and Cameron, \{D. A.\} and A. Wardley",

year = "2021",

month = jan,

doi = "10.1016/j.clon.2020.07.006",

language = "אנגלית",

volume = "33",

pages = "15--19",

journal = "Clinical Oncology",

issn = "0936-6555",

publisher = "Elsevier Ltd.",

number = "1",

}

Earl, HM, Hiller, L, Dunn, J, Macpherson, I, Rea, D, Hughes-Davies, L, McAdam, K, Hall, P, Mansi, J, Wheatley, D, Abraham, JE, Caldas, C, Gasson, S, O'Riordan, E, Wilcox, M, Miles, D, Cameron, DA & Wardley, A 2021, 'Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK', Clinical Oncology, vol. 33, no. 1, pp. 15-19. https://doi.org/10.1016/j.clon.2020.07.006

TY - JOUR

T1 - Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK

AU - Earl, H. M.

AU - Hiller, L.

AU - Dunn, J.

AU - Macpherson, I.

AU - Rea, D.

AU - Hughes-Davies, L.

AU - McAdam, K.

AU - Hall, P.

AU - Mansi, J.

AU - Wheatley, D.

AU - Abraham, J. E.

AU - Caldas, C.

AU - Gasson, S.

AU - O'Riordan, E.

AU - Wilcox, M.

AU - Miles, D.

AU - Cameron, D. A.

AU - Wardley, A.

PY - 2021/1

Y1 - 2021/1

UR - https://www.scopus.com/pages/publications/85088800392

U2 - 10.1016/j.clon.2020.07.006

DO - 10.1016/j.clon.2020.07.006

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.editorial???

C2 - 32723485

AN - SCOPUS:85088800392

SN - 0936-6555

VL - 33

SP - 15

EP - 19

JO - Clinical Oncology

JF - Clinical Oncology

IS - 1

ER -

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK

UN SDGs

Access to Document

Other files and links

Cite this